Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Chitra Chitra Hosing, MD
CONTACT
Lead
M.D. Anderson Cancer Center
Primary Objectives: To determine the safety, tolerability and optimal cell dose of AD-PluReceptor plus Tafasitamab cxix and lymphodepleting chemotherapy in patients with systemic sclerosis and systemic lupus erythematosus (including lupus nephritis). Secondary Objectives: To assess the overall response rate. To evaluate the persistence and kinetics of infused allogeneic donor AD-PluReceptor cells in the recipient. To conduct comprehensive immune reconstitution studies. To evaluate the number of patients not requiring any systemic immunosuppressive therapy for their autoimmune disease at 1 year post infusion.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted